Does Cannabis Help Reduce Caregiver Stress in Dementia Care?

PostedMarch 9, 2026

UpdatedMarch 9, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Caring for someone with dementia can be emotionally and physically exhausting. Many carers report high levels of stress, especially when managing agitation, sleep disruption, or behavioural changes in their loved ones. With growing public discussion around medical cannabis, some wonder whether it might ease symptoms in people with dementia and in turn, reduce the stress on family caregivers.

According to current NHS and NICE guidance, there is no evidence that medical cannabis directly reduces caregiver stress or provides reliable relief for dementia symptoms that contribute to caregiver burden.

What The Evidence Shows

NICE guidance on Cannabis-based Medicinal Products (NG144) makes clear that cannabis-based medicines (CBMPs) are not recommended for the behavioural or psychological symptoms of dementia. NICE notes that any use should occur only within approved research trials because evidence remains too weak and inconsistent for routine NHS use.

The NHS also states that medical cannabis is not licensed as a treatment for dementia. There is currently no robust clinical proof that CBMPs improve agitation, sleep, or anxiety in a way that would meaningfully reduce stress for caregivers.

According to the Alzheimer’s Society UK, most research on cannabinoids such as THC and CBD has focused on short-term effects in people with dementia, not on caregiver outcomes. Some small pilot trials have reported slight improvements in agitation or sleep, but results are inconsistent, short-lived, and often involve fewer than 100 participants.

Recent studies supported by Alzheimer’s Research UK and the Cochrane Dementia and Cognitive Improvement Group (2022) confirm that there is still no reliable evidence that cannabinoids improve dementia symptoms enough to reduce caregiver stress.

The Clinical Bottom Line

Cannabis-based medicinal products are not approved for managing dementia-related symptoms in the UK.

NICE and NHS recommend CBMPs only within controlled research settings.

No studies have shown a direct or consistent reduction in caregiver stress.

Evidence for benefits in agitation or sleep is weak and temporary.

Potential side effects such as confusion, sedation, and falls may increase care demands.

Support for carers remains best achieved through psychological, community, and respite interventions.

What This Means in Practice

At present, medical cannabis is not a recognised or proven way to reduce stress in dementia caregiving. The most effective approaches for supporting carers remain practical support, respite care, and evidence-based behavioural strategies.

About AlleviMed

Organisations such as AlleviMed provide educational information about how UK eligibility for medical cannabis is assessed, helping families understand the legal and clinical frameworks surrounding CBMPs, but do not offer prescribing or treatment services.

Takeaway

Current evidence does not support the use of cannabis to reduce caregiver stress in dementia care. According to NHS, NICE, and the Alzheimer’s Society, CBMPs should only be considered within formal research trials until stronger; long-term evidence becomes available.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.